Maxim Group LLC acted as the exclusive placement agent for the registered direct offering and concurrent private placement. The gross proceeds to the Company from the offering are approximately $2 ...

SYDNEY, Jan. 14, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Kazia Therapeutics (KZIA) announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 1,333,333 of the company’s American Depositary Shares, each ...

Kazia Therapeutics Limited (NASDAQ:KZIA) stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting with ...

Kazia Therapeutics (Nasdaq: KZIA), an oncology-focused Australian drug developer, has been advised by the US Food and Drug Administration that accelerated approval for its brain cancer drug, paxalisib ...